Benzodiazepine use, quality of life and psychiatric symptom burden in oral and injectable opioid agonist treatment: a cross-sectional study

Benzodiazepine use, quality of life and psychiatric symptom burden in oral and injectable opioid agonist treatment: a cross-sectional study

Abstract Background Use of benzodiazepines (BZD) in patients receiving opioid agonist treatment (OAT) is common and associated with a variety of negative health and social outcomes. This cross-sectional study investigates the impact of BZD use in OAT patients on their quality of life (QoL). Methods...

Full description

Bibliographic Details
Main Authors: Maximilian Meyer, Ferdinand Gygli, Jean N. Westenberg, Otto Schmid, Johannes Strasser, Undine E. Lang, Kenneth M. Dürsteler, Marc Vogel
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Addiction Science & Clinical Practice
Subjects:
Opioid use disorder
Quality of life
Methadone maintenance treatment
Heroin-assisted treatment
Substitution treatment
Sedative
Online Access:https://doi.org/10.1186/s13722-023-00397-8

Internet

https://doi.org/10.1186/s13722-023-00397-8

Similar Items